In recent years, triple-acting agents simultaneously inhibiting DAT, NET, and SERT have been actively developed for treating depression because they have a faster onset of action and better efficacy than current antidepressants due to their dopamine components [4]. The gene discussed is SLC6A3; the disease is depressive disorder.